Sign in Create account

Sanofi Consumer Healthcare India Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: SANOFICONR BSE: 544250
₹3802.80
▼ -64.20 (-1.66%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
85/100
Strong
Valuation
36/100
Fairly Valued
Momentum
8/100
Bearish

QVM read Quality business Quality Strong, Valuation Fairly Valued, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹8,758 Cr
PE (TTM)
32.9
Industry median 36.1 (152 companies)
Price to Book
22.8
PEG (TTM)
1.0
Institutions holding %
20.46%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
-11.4
Relative return vs Sector, qtr %
-17.5
Free Cash Flow
₹144 Cr
as of June 30, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
13.32%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
33.00%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
31.17%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
13.34%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
6.70%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
3.85
as of Dec. 31, 2025
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of Dec. 31, 2025
Industry median 0.14 (186 companies)
Interest Coverage
179.60
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
29.19%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
39.16%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
37.82%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
43.89%
as of Dec. 31, 2025
Industry median 5.54% (180 companies)
Return on Capital Employed
76.99%
as of Dec. 31, 2025
Industry median 12.43% (181 companies)
Return on Equity
62.53%
as of Dec. 31, 2025
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

6 of 6 met
  • Yes Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • Yes Return on equity is 15% or more (62.5%)
  • Yes Net cash flow for the latest year is positive

Ownership

4 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.7%
Low 3796.0000 · High 3919.0000
1W return
-5.1%
Low 3796.0000 · High 4068.4000
1M return
-8.1%
Low 3796.0000 · High 4287.9000
52W return
-19.9%
Low 3796.0000 · High 5255.0000
Lifetime High ₹5696.0000 (June 30, 2025)
Lifetime Low ₹3802.8000 (Sept. 30, 2026)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
3895.0
10D
3945.6
20D
4022.3
50D
4203.3
100D
4331.5
200D
4432.4

Delivery and volume

Day avg. delivery
56.5%
Week avg. delivery
49.6%
Month avg. delivery
56.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

3839.27
Pivot
First resistance3882.53
Second resistance3962.27
Third resistance4005.53
First support3759.53
Second support3716.27
Third support3636.53
Day RSI24.2
Day MFI19.6
Day MACD-103.49
Day MACD signal-97.87

Beta

1M-0.03
3M0.17
1Y0.47
3Y0.32

Price change analysis

↓ -8.1%
Over 1 Month
LowHigh
3796.004287.90
↓ -17.5%
Over 3 Months
LowHigh
3796.004927.00
↓ -16.2%
Over 6 Months
LowHigh
3796.005255.00
↓ -19.9%
Over 1 Year
LowHigh
3796.005255.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 32.9 (own history: 38.4–66.1)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹236 Cr
Net profit (June 30, 2026)
₹69 Cr
Basic EPS (June 30, 2026)
₹29.8700

Ranks #47 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter71.27%
  • Mutual funds13.01%
  • FII/FPI2.60%
  • Other DII4.85%
  • Public8.27%

Largest holders

NameCategoryShares %Shares
Opella Healthcare Participations B.V.Promoter60.4000%13909587
Opal Bidco SASPromoter10.8800%2504630
Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap FundPublic5.2100%1200657
Aditya Birla Sun Life Trustee Private Limited A/C - Aditya Birla Sun Life Large Cap FundPublic3.0300%696684
Hdfc Life Insurance Company LimitedPublic2.1200%488448

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 71.27% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 2.76% to 2.60% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 13.63% to 13.01% in Jun 2026 qtr

12 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 5 insider trades, 7 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
16 Jun 2025 Opal Bidco SAS Promoter group Buy 0 ₹0
31 Oct 2024 Opella Healthcare Participations B.V. Promoter Buy 0 ₹0
31 Oct 2024 SANOFI Promoter Sell 0 ₹0
23 Oct 2024 Hoechst GmbH Promoter Sell 0 ₹0
23 Oct 2024 Opella Healthcare Participations B.V. Promoter group Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 4 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
10 Oct 2024 HOECHST GMBH Block Sell 13,904,722 4982.0500 BSE
10 Oct 2024 OPELLA HEALTHCARE PARTICIPATIONS B V Block Buy 13,904,722 4982.0500 BSE
10 Oct 2024 OPELLA HEALTHCARE PARTICIPATIONS B V Bulk Buy 13,904,722 4982.0500 BSE
10 Oct 2024 HOECHST GMBH Bulk Sell 13,904,722 4982.0500 BSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹75.00 per share
Dividend yield 1.97%
Ex-dateSubjectPer share (₹)Record date
19 Jun 2026 Dividend - Rs 75 Per Share 75.0000 19 Jun 2026
17 Apr 2025 Dividend - Rs 55 Per Share 55.0000 17 Apr 2025

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
28 Jul 2026 Financial Results Yes
28 Apr 2026 Financial Results Yes
25 Feb 2026 Dividend —
25 Feb 2026 Financial Results Yes
12 Nov 2025 Financial Results Yes

Corporate Announcements

All 139 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
28 Sep 2026 Insider Trading / SAST Sanofi Consumer Healthcare India Ltd - 544250 - Closure of Trading Window
28 Sep 2026 Trading Window Sanofi Consumer Healthcare India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
30 Jul 2026 Copy of Newspaper Publication Sanofi Consumer Healthcare India Limited has informed the Exchange about Copy of Newspaper Publication of Unaudited Financial Result for the quarter and half year ended 30th June 2026.
28 Jul 2026 Press Release Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated July 28, 2026.
28 Jul 2026 Outcome of Board Meeting Sanofi Consumer Healthcare India Limited has submitted to the Exchange, the Unaudited Financial Results for the quarter and half year ended Jun 30, 2026.
9 Jul 2026 Certificate under SEBI (Depositories and Participants) Regulations, 2018 Sanofi Consumer Healthcare India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
29 Jun 2026 Change in Auditors Sanofi Consumer Healthcare India Limited has informed the Exchange regarding Change in Auditors of the company.
29 Jun 2026 Shareholders meeting Sanofi Consumer Healthcare India Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on Jun 26, 2026. Further, the company has informed the Exchange regarding voting results.
26 Jun 2026 Shareholders meeting Sanofi Consumer Healthcare India Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on June 26, 2026
26 Jun 2026 Trading Window Sanofi Consumer Healthcare India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • High Return on Equity (62.5%)
  • Strong net profit margin (29.2%)
  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (179.6x)

Weaknesses

Data unavailable.

Opportunities

  • PEG below 1 (1.00) -- earnings growth outpacing its own valuation
  • RSI in oversold territory (24.2) -- a technical rebound zone

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Sanofi Consumer Healthcare India Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.